<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00477152</url>
  </required_header>
  <id_info>
    <org_study_id>1838-003</org_study_id>
    <nct_id>NCT00477152</nct_id>
  </id_info>
  <brief_title>Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase for Infants and Children</brief_title>
  <acronym>INFUSE-PR</acronym>
  <official_title>INcreased Flow Utilizing Subcutaneously-Enabled Pediatric Rehydration (INFUSE-Pediatric Rehydration Study): Phase IV Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase (HYLENEX) for Infants and Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Halozyme Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the safety, effectiveness and ease of use of subcutaneous
      (SC) rehydration using HYLENEX-augmented SC infusion of fluids and electrolytes for the
      rehydration of pediatric patients with mild to moderate dehydration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pediatric patients (2 months to 10 years of age), presenting to the emergency department (ED)
      with mild to moderate dehydration and requiring parenteral rehydration, were treated with
      HYLENEX-augmented subcutaneous (SC) rehydration. An initial volume of 20 mL/kg of isotonic
      fluid was to be administered by continuous SC infusion over the first hour, and additional SC
      rehydration could be continued as clinically indicated. The preferred anatomic site for the
      SC infusion was the anterior thigh, unless there was an overriding preference for an
      alternate site.

      The duration of HYLENEX-augmented SC rehydration was to be a minimum of 1 hour and a maximum
      of 72 hours. The investigator or designee performed a clinical assessment of the subject's
      hydration status at baseline and at the end of SC infusion or at discharge from the ED. Other
      assessments of effectiveness and safety were made directly during the rehydration period and
      ED stay, and by telephone on Days 3 and 7 after discharge from the ED.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HYLENEX-facilitated Subcutaneous (SC) Rehydration Success</measure>
    <time_frame>At emergency department discharge (mean time to discharge = 7.03 ± 7.57 hr)</time_frame>
    <description>Successfully rehydrated (as medically judged by treating physician) without rescue therapy (ie, without receiving fluids via an alternate route), and discharged to home</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified HYLENEX-facilitated Subcutaneous (SC) Rehydration Success</measure>
    <time_frame>At emergency department discharge (mean time to discharge = 7.03 ± 7.57 hr)</time_frame>
    <description>Successfully rehydrated (as medically judged by treating physician) without rescue therapy (ie, without receiving fluids via an alternate route), regardless of emergency department discharge destination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Attempts Needed to Successfully Place Subcutaneous (SC) Catheter</measure>
    <time_frame>At end of placement of SC catheter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Gorelick Dehydration Score</measure>
    <time_frame>At baseline and at either the end of subcutaneous infusion (mean duration = 5.73 ± 9.15 hr) or emergency department discharge (mean time to discharge = 7.03 ± 7.57 hr)</time_frame>
    <description>Score indicates the number of moderate-to-severe signs/symptoms of dehydration, based on assessment of each of the following 10 patient parameters: general condition, quality of radial pulse, quality of respiration, skin elasticity, eyes, tears, mucous membranes, urine output, heart rate and fingertip capillary refill time. Minimum score = 0; maximum score = 10.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Dehydration</condition>
  <arm_group>
    <arm_group_label>HYLENEX-augmented subcutaneous (SC ) rehydration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hyaluronidase (human recombinant)/rehydration fluid</intervention_name>
    <description>Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.</description>
    <arm_group_label>HYLENEX-augmented subcutaneous (SC ) rehydration</arm_group_label>
    <other_name>HYLENEX recombinant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Child, 2 months to 10 years of age

          -  Body weight less than 42 kg

          -  Presenting at emergency department with mild to moderate dehydration (Gorelick
             dehydration classification: presence of 1 to 6 [of possible 10] moderate or severe
             signs and symptoms) requiring parenteral rehydration

        Exclusion Criteria:

          -  In shock or life-threatening situation (other than dehydration)

          -  Severe dehydration

          -  Requires intravenous (IV) therapy for another indication

          -  Indwelling IV catheter (excepting one intended strictly for clinical laboratory sample
             collection)

          -  Already received rehydration therapy IV within prior 48 hours or substantial oral
             fluid immediately before enrollment

          -  Condition precluding subcutaneous injection or infusion site evaluation in anterior
             thigh or other elected infusion site

          -  Reason for hospital admission or extended emergency department stay other than
             dehydration

          -  Known hypersensitivity to hyaluronidase or another ingredient in HYLENEX

          -  Hyponatremia or hypernatremia

          -  Hypokalemia

          -  Medical condition likely to interfere with ability to fully complete study or have
             protocol-specified assessments

          -  Medical history, screening examination finding or historical clinical laboratory
             result precluding safe participation in study or which might adversely effect
             interpretation of study results

          -  Participated in study of any investigational drug or device within 30 days prior to
             this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George E Harb, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Healthcare Corporation</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Gorelick MH, Shaw KN, Murphy KO. Validity and reliability of clinical signs in the diagnosis of dehydration in children. Pediatrics. 1997 May;99(5):E6.</citation>
    <PMID>9113963</PMID>
  </reference>
  <results_reference>
    <citation>Allen CH, Etzwiler LS, Miller MK, Maher G, Mace S, Hostetler MA, Smith SR, Reinhardt N, Hahn B, Harb G; INcreased Flow Utilizing Subcutaneously-Enabled Pediatric Rehydration Study Collaborative Research Group. Recombinant human hyaluronidase-enabled subcutaneous pediatric rehydration. Pediatrics. 2009 Nov;124(5):e858-67. doi: 10.1542/peds.2008-3588. Epub 2009 Oct 5.</citation>
    <PMID>19805455</PMID>
  </results_reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2007</study_first_submitted>
  <study_first_submitted_qc>May 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2007</study_first_posted>
  <results_first_submitted>September 12, 2011</results_first_submitted>
  <results_first_submitted_qc>October 18, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 23, 2011</results_first_posted>
  <last_update_submitted>November 22, 2011</last_update_submitted>
  <last_update_submitted_qc>November 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dehydration</keyword>
  <keyword>fluid therapy</keyword>
  <keyword>pediatrics</keyword>
  <keyword>emergency medicine</keyword>
  <keyword>hyaluronoglucosaminidase</keyword>
  <keyword>hyaluronidase</keyword>
  <keyword>hypodermoclysis</keyword>
  <keyword>clysis</keyword>
  <keyword>subcutaneous hydration</keyword>
  <keyword>subcutaneous rehydration</keyword>
  <keyword>hyaluronan</keyword>
  <keyword>rHuPH20</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydration</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects recruited in emergency department after presenting with signs of mild to moderate dehydration</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>HYLENEX-augmented Subcutaneous (SC) Rehydration</title>
          <description>Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52">One patient withdrawn prior to treatment, so not included in analyses.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49">Two patients treated, but assessments incomplete. All available data included in analyses for these.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Parent withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HYLENEX-augmented Subcutaneous (SC) Rehydration</title>
          <description>Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.91" spread="1.949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;= 2 months to &lt; 3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 3 years to &lt;= 10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gorelick Dehydration Score</title>
          <description>Score indicates the number of moderate-to-severe signs/symptoms of dehydration, based on assessment of each of the following ten patient parameters: general condition, quality of radial pulse, quality of respiration, skin elasticity, eyes, tears, mucous membranes, urine output, heart rate and fingertip capillary refill time. Minimum score = 0; maximum score = 10. (Note: study inclusion criterion required a baseline score of 1 to 6.)</description>
          <units>Number of moderate/severe symptoms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HYLENEX-facilitated Subcutaneous (SC) Rehydration Success</title>
        <description>Successfully rehydrated (as medically judged by treating physician) without rescue therapy (ie, without receiving fluids via an alternate route), and discharged to home</description>
        <time_frame>At emergency department discharge (mean time to discharge = 7.03 ± 7.57 hr)</time_frame>
        <population>ITT (all treated patients)</population>
        <group_list>
          <group group_id="O1">
            <title>HYLENEX-augmented Subcutaneous (SC) Rehydration</title>
            <description>Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>HYLENEX-facilitated Subcutaneous (SC) Rehydration Success</title>
          <description>Successfully rehydrated (as medically judged by treating physician) without rescue therapy (ie, without receiving fluids via an alternate route), and discharged to home</description>
          <population>ITT (all treated patients)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Modified HYLENEX-facilitated Subcutaneous (SC) Rehydration Success</title>
        <description>Successfully rehydrated (as medically judged by treating physician) without rescue therapy (ie, without receiving fluids via an alternate route), regardless of emergency department discharge destination</description>
        <time_frame>At emergency department discharge (mean time to discharge = 7.03 ± 7.57 hr)</time_frame>
        <population>ITT (all treated patients)</population>
        <group_list>
          <group group_id="O1">
            <title>HYLENEX-augmented Subcutaneous (SC) Rehydration</title>
            <description>Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified HYLENEX-facilitated Subcutaneous (SC) Rehydration Success</title>
          <description>Successfully rehydrated (as medically judged by treating physician) without rescue therapy (ie, without receiving fluids via an alternate route), regardless of emergency department discharge destination</description>
          <population>ITT (all treated patients)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Attempts Needed to Successfully Place Subcutaneous (SC) Catheter</title>
        <time_frame>At end of placement of SC catheter</time_frame>
        <population>ITT (all treated patients)</population>
        <group_list>
          <group group_id="O1">
            <title>HYLENEX-augmented Subcutaneous (SC) Rehydration</title>
            <description>Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Attempts Needed to Successfully Place Subcutaneous (SC) Catheter</title>
          <population>ITT (all treated patients)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 attempts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Gorelick Dehydration Score</title>
        <description>Score indicates the number of moderate-to-severe signs/symptoms of dehydration, based on assessment of each of the following 10 patient parameters: general condition, quality of radial pulse, quality of respiration, skin elasticity, eyes, tears, mucous membranes, urine output, heart rate and fingertip capillary refill time. Minimum score = 0; maximum score = 10.</description>
        <time_frame>At baseline and at either the end of subcutaneous infusion (mean duration = 5.73 ± 9.15 hr) or emergency department discharge (mean time to discharge = 7.03 ± 7.57 hr)</time_frame>
        <population>ITT (all treated patients)</population>
        <group_list>
          <group group_id="O1">
            <title>HYLENEX-augmented Subcutaneous (SC) Rehydration</title>
            <description>Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Gorelick Dehydration Score</title>
          <description>Score indicates the number of moderate-to-severe signs/symptoms of dehydration, based on assessment of each of the following 10 patient parameters: general condition, quality of radial pulse, quality of respiration, skin elasticity, eyes, tears, mucous membranes, urine output, heart rate and fingertip capillary refill time. Minimum score = 0; maximum score = 10.</description>
          <population>ITT (all treated patients)</population>
          <units>No. moderate/severe symptoms (max = 10)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Actual Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>HYLENEX-augmented Subcutaneous (SC) Rehydration</title>
          <description>Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infusion site cellulitis</sub_title>
                <description>Unrelated to HYLENEX</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site erythema</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Infusion site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Infusion site rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Infusion site swelling</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Baxter's agreements with PIs vary per individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 1 year after study completion. Baxter requires a review of results communications (eg, for confidential information) up to 90 days prior to submission or communication. Baxter may request an additional delay of up to 60 days (eg, to allow for intellectual property protection).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>George Harb, MD, MPH</name_or_title>
      <organization>Baxter Halthcare Corporation</organization>
      <email>george_harb@baxter.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

